Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Kidney Int. 2013 Sep 11;85(4):807–823. doi: 10.1038/ki.2013.345

Figure 3. Reduced kidney endothelial S1P1R protein expression in conditional endothelial S1P1R null (S1P1Rf/f PdgfbiCreER) mice.

Figure 3

Figure 3

A. Representative images (magnification 600X) for S1P1R and CD34 immunoreactivity (brown stain, arrows) in kidney blood vessels from tamoxifen-treated S1P1Rf/f PdgfbiCreER and S1P1Rf/f mice. S1P1R immunoreactivity was drastically reduced (near absent) in tamoxifen-treated S1P1Rf/f PdgfbiCreER mice when compared to S1P1Rf/f mice. S1P1R immunoreactivity was still visible from intravascular leukocytes in conditional endothelial S1P1R null mice. CD34 immunoreactivity was similar between tamoxifen-treated S1P1Rf/f PdgfbiCreER mice and S1P1Rf/f mice. Representative of 4 experiments. B. Representative images (magnification 600X) for S1P1R and CD34 immunoreactivity (brown stain, arrows) in peritubular capillaries and glomeruli from tamoxifen-treated S1P1Rf/f PdgfbiCreER and S1P1Rf/f mice. S1P1R immunoreactivity was absent in peritubular capillaries and glomeruli from tamoxifen-treated S1P1Rf/f PdgfbiCreER mice when compared to S1P1Rf/f mice. Again, leukocyte S1P1R immunoreactivity was visible in kidneys from conditional endothelial S1P1R null mice. CD34 immunoreactivity was similar between tamoxifen-treated S1P1Rf/f PdgfbiCreER mice and S1P1Rf/f mice. Representative of 4 experiments.